-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/dementia-nursing-home-characteristics_disposition-comments.pdf
October 23, 2012 - TEP Reviewer
#1
Executive
Summary
ES-14, line 10: Can applicability be better discussed? … This consideration was discussed with our
Technical Expert Panel, as well. … Peer Reviewer
#1
Discussion There are findings, and they are discussed very nicely. … We discussed blinding and sample size as research
challenges to point out that to determine the effectiveness … The authors and TEP undoubtedly discussed such a
logic train in detail.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cerebral-palsy-feeding_disposition-comments.pdf
March 20, 2013 - Peer reviewer
#4
Discussion/conclusion Some research gaps are discussed and the need for good
RCT … conclusion The ethical implications of conducting comparative studies
of surgical interventions is discussed … yes
Limitation adequately discussed? yes Omission of
literature?
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/mhs4-infection-prevention-mdro-rapid-research.pdf
April 01, 2024 - associated pneumonia/events (VAP/VAE), surgical site infection
(SSI), surveillance testing (will be discussed … separate MHS IV chapter), as well as
the broader practices of antimicrobial stewardship (which was discussed … Conflicts were discussed and resolved during a team
meeting. … The authors discussed in detail a number of methodologic and analytic
problems with studies, including … There was also literature
which discussed the use of several of these practices in combination in long-term
-
effectivehealthcare.ahrq.gov/sites/default/files/celiac-disease_disposition-comments.pdf
January 28, 2016 - These
studies were relatively rare; but we did include some
and their strengths and weakness are discussed … Commentator
& Affiliation
Section Comment Response
report so that VCE is always discussed after … One issue that
can be additionally discussed is the different HLA
DQ2 haplotypes and methods for HLA … This issue is now discussed in the
Executive Summary and Discussion section under
“Applicability.”
-
effectivehealthcare.ahrq.gov/sites/default/files/ch_2-user-guide-to-ocer_130129.pdf
January 01, 2011 - the appropriate data source, patient population,
inclusion/exclusion criteria, and comparators are discussed … As discussed, the cohort design provided
a clear timeline, differentiating exposure from
potential … should be the default design for CER
studies; deviations should be argued for and their
consequences discussed … Some additional study designs have not been
discussed. … Many of the issues that will be
discussed in the following chapters about ways to
deal with treatment
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/healthcare-infections_disposition-comments.pdf
August 10, 2015 - However,
we focused the report on the three
pathogens of interest as discussed above. … Part of this is discussed in
the section on patient safety culture (page 16 and
following), but a key … While the ‘cidal’ activity of each of
the surface disinfectants is discussed, this isn’t addressed … Our systematic searches did not identify any
studies that specifically examined or
discussed the percent … It really is that they have “not been
established”, as previously discussed.
-
effectivehealthcare.ahrq.gov/sites/default/files/worker-health_disposition-comments.pdf
May 31, 2016 - Key Question 1 does not include the
need to assess what is meant by integration nor the issues
discussed … The timing of the studies should have been
discussed in relation to the development of the TWH
definition … The authors should add a
discussion of limitations discussed in the response to
question 1 of this … TWH may well have value, but for the
reasons stated above and many more discussed by the authors, there … Key Question 1 does not include the need to assess what is meant by
integration nor the issues discussed
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/major-depressive-disorder-disposition-160504.pdf
December 08, 2015 - Another issue that needs to be
more explicitly discussed is that there may well be sample bias
depending … I believe that
the approaches being discussed in this review are better described as
complementary … Indeed each of the treatment
approaches, such as acupuncture is discussed in conjunction with SGA, … The same
would be true elsewhere in the document and abstract
where acupuncture is discussed. … This is problematic for the reasons discussed above.
Thank you for the comment.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-196-disposition-comments-immunotherapy-asthma.pdf
March 23, 2018 - The reason for performing this review is nicely
discussed.
Thank you for your comment. … in this paragraph, but prior to this paragraph no other
studies have been cited in this way when discussed … It is further recommended that this omission should also be
discussed carefully in the Discussion Section … in the discussion,
otherwise it is not clear if it is antigen specific or total IgE that is
being discussed … Individual reactions will be
discussed in their respective RCT and non-
RCT categories." therefore we
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/field-triage-glascow-disposition-170415.pdf
January 12, 2017 - , described
in the Methods section, two reviewers
independently rated the quality of each study,
discussed … This is discussed in the article
cited by the reviewer: “simpler scales perform
just as well.” tGCS … As described in the Methods section, two
reviewers independently rated the quality of all
studies, discussed … Response
Peer Reviewer #5 Results I guess the one thing that is not clear in the way the
results are discussed … I realize this is discussed on page 55 but I
think you can be less perfunctory here or repeat it in
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/asthma-provider-adherence_disposition-comments.pdf
May 19, 2013 - Key Question
3
I believe that improved control is a patient outcome of significance that is
not discussed … Magnitude is listed on the data tables
but is not always discussed.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/asd-interventions-disposition.pdf
May 26, 2017 - and I believe this is not adequately accounted for in the
assessment of the studies, or adequately discussed … Cochrane)and discussed why the results of those reviews might differ
from the AHRQ.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/hypothyroidism-hyperthyroidism-screening-treatment_disposition-comments.pdf
February 01, 2012 - , 2nd We have added language briefly describing
the Whickham study in the paragraph in
which it's discussed … agree that this might be the case, but we
would need future research to confirm and
have briefly discussed … Again the last sentence (line 12-14) is
problematic as this is not referenced or further discussed in
-
effectivehealthcare.ahrq.gov/sites/default/files/cer-236-maternal-fetal-child-outcomes-disposition-comments.pdf
April 15, 2021 - For all of the other
major complications that are discussed in the review, it
would be useful to include … It would also be
helpful to include information on neonatal adaptation
syndrome, which is not discussed … than as part of the information on respiratory difficulties
where some of this information is already discussed … Particularly if the studies are often discussed or
cited by other reviews or meta-analyses, it is important
-
effectivehealthcare.ahrq.gov/sites/default/files/fecal-incontinence_disposition-comments.pdf
March 21, 2016 - We discussed the
non-neurologic and neurologic distinction with
our experts prior to this review (KIs … quality of the literature evidence for SNS to
date is weak due to methodological limitations
that were discussed … One the most common outcome measure, the
bowel diary, is not well-discussed as a tool to measure FI
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/liver-cancer-therapy_disposition-comments.pdf
May 24, 2013 - line 53: This patient population
comprises the group typically considered eligible
for the therapies discussed … Technical Expert #5 Discussion/
Conclusion
Implications and limitations discussed clearly Thank you … population most accurately reflects
the patient population considered eligible for local
therapies discussed … Reviewer #2
Results I note a large retrospective case control study
relevant to the article is not discussed
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/measuring-blood-pressure_disposition-comments.pdf
January 01, 2012 - We discussed whether we should include studies that
employed self bp measurement not at home (eg in … As discussed
on p 138, the ongoing HOMED-BP study aims to
determine an optimal target BP level on the … This was not omitted: We discussed our findings in the
context of Agarwal’s 2011 systematic review in … As discussed above we added this
sentence to the future research needs section: “Many
clinicians consider
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/rtc-design-principles_research.pdf
January 01, 2009 - used to map out critical comparisons, select evidence, and judge the need for a
long-term RCT are discussed … to the extra cases detected by the new test if they represent a different
spectrum of disease, as discussed … sensitive test for those testing negative
6
on the existing test, as shown in Figure 1b and discussed … These
issues are discussed separately below.
Test-treatment pathway
Treatment effects.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/breast-biopsy_disposition-comments.pdf
March 11, 2010 - However, as discussed in our Methods
section, the literature on core-needle breast biopsy
accuracy … procedure the risks of breast cancer that are associated with prior
benign breast biopsies should be discussed … This is
currently discussed on page 25 under “multiple methods” but is
easily overlooked there. … Results p. 23, Liberman et al. 1994 have a study on how many cores are
enough this should be cited and discussed
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/mrsa-screening-2010_disposition-comments.pdf
January 01, 2010 - The epidemiology is briefly discussed as are
conventional strategies for MRSA control. … While the findings are not conclusive, this topic should be discussed in more
depth. … This subject is discussed in the
Introduction. … We have discussed
these issues in the report. … We have discussed this concern as a potential
harm of screening for MRSA carriage.